Literature DB >> 1643622

Vascular malformation with radiation vasculopathy after treatment of chiasmatic/hypothalamic glioma.

M A Epstein1, R J Packer, L B Rorke, R A Zimmerman, J W Goldwein, L N Sutton, L Schut.   

Abstract

Chiasmatic/hypothalamic gliomas usually are histologically benign astrocytomas that may recur many years after diagnosis and treatment. Three children with chiasmatic/hypothalamic gliomas who were treated at the authors' institution returned 9.5, 11.5, and 2 years, respectively, after radiation therapy (RT) because visual and neurologic deterioration developed. Neuroradiographic studies, including arteriography in two of the patients, showed large mass lesions. These were presumed to be recurrence of tumor, and chemotherapy was administered. Pathologic examination of two children who died and of the third who had a biopsy revealed only a minimal amount of residual, histologically benign astrocytoma, whereas the bulk of the specimen consisted of numerous vessels of variable size. These probably represented incorporation of the rich vasculature in the chiasmal region into the tumor, which underwent degeneration secondary to RT. Radiographic methods did not distinguish progressive tumor growth from the vasculopathy and led to inappropriate clinical diagnoses and treatment.

Entities:  

Mesh:

Year:  1992        PMID: 1643622     DOI: 10.1002/1097-0142(19920815)70:4<887::aid-cncr2820700427>3.0.co;2-9

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Visual pathway glioma: an erratic tumour with therapeutic dilemmas.

Authors:  A Shuper; G Horev; L Kornreich; S Michowiz; R Weitz; R Zaizov; I J Cohen
Journal:  Arch Dis Child       Date:  1997-03       Impact factor: 3.791

Review 2.  Spontaneous regression of optic pathways gliomas in three patients with neurofibromatosis type I and critical review of the literature.

Authors:  Manolo Piccirilli; Jacopo Lenzi; Catia Delfinis; Guido Trasimeni; Maurizio Salvati; Antonino Raco
Journal:  Childs Nerv Syst       Date:  2006-04-26       Impact factor: 1.475

3.  Visual outcomes in pediatric optic pathway glioma after conformal radiation therapy.

Authors:  Richard M Awdeh; Erin N Kiehna; Richard D Drewry; Natalie C Kerr; Barrett G Haik; Shengjie Wu; Xiaoping Xiong; Thomas E Merchant
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-05-18       Impact factor: 7.038

Review 4.  Advances in the management of low-grade gliomas.

Authors:  Amulya A Nageswara Rao; Roger J Packer
Journal:  Curr Oncol Rep       Date:  2014       Impact factor: 5.075

Review 5.  Review of cranial radiotherapy-induced vasculopathy.

Authors:  Erin S Murphy; Hao Xie; Thomas E Merchant; Jennifer S Yu; Samuel T Chao; John H Suh
Journal:  J Neurooncol       Date:  2015-02-12       Impact factor: 4.130

6.  Moyamoya syndrome: post cranial irradiation of pineal gland tumor.

Authors:  P Chiewvit; V Janyavanich; N Soonthonpong; A Churoj; O Chawalparit; S Suthipongchai
Journal:  Interv Neuroradiol       Date:  2001-07-15       Impact factor: 1.610

7.  Cranial irradiation increases risk of stroke in pediatric brain tumor survivors.

Authors:  Cynthia J Campen; Sarah M Kranick; Scott E Kasner; Sudha K Kessler; Robert A Zimmerman; Robert Lustig; Peter C Phillips; Phillip B Storm; Sabrina E Smith; Rebecca Ichord; Michael J Fisher
Journal:  Stroke       Date:  2012-09-11       Impact factor: 7.914

8.  Late effects of conformal radiation therapy for pediatric patients with low-grade glioma: prospective evaluation of cognitive, endocrine, and hearing deficits.

Authors:  Thomas E Merchant; Heather M Conklin; Shengjie Wu; Robert H Lustig; Xiaoping Xiong
Journal:  J Clin Oncol       Date:  2009-07-06       Impact factor: 44.544

Review 9.  Inherited and acquired risk factors for arterial ischemic stroke in childhood.

Authors:  Giuseppe Lippi; Massimo Franchini; Martina Montagnana; Gian Luca Salvagno; Giovanni Targher; Gian Cesare Guidi
Journal:  J Thromb Thrombolysis       Date:  2008-02-10       Impact factor: 2.300

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.